Shaping the Future of Rare Diseases after a Global Health Emergency: Organisational Points to Consider.

COVID-19 health emergencies health policies healthcare organization organizational models rare diseases rare diseases networks

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
23 11 2020
Historique:
received: 29 09 2020
revised: 18 11 2020
accepted: 21 11 2020
entrez: 26 11 2020
pubmed: 27 11 2020
medline: 15 12 2020
Statut: epublish

Résumé

The unexpected outbreak of the COVID-19 disease had significant and enormous repercussions on the healthcare systems, such as the need to reorganise healthcare organisations in order to concentrate resources needed to the care of COVID-19 patients and to respond in general to this health emergency. Due to these challenges, the care of several chronic conditions was in many cases discontinued and patients and healthcare professionals treating these conditions had to cope with this new scenario. This was the case of the world rare diseases (RDs) that had to face this global emergency despite the vulnerability of people with RDs and the well-known need for high expertise required to treat and manage them. The numerous lessons learned so far regarding health emergencies and RDs should represent the basis for the establishment of new healthcare policies and plans aimed at ensuring the preparedness of our health systems in providing appropriate care to people living with RDs in the case of eventual new emergencies. This paper aims at providing pragmatic considerations that might be useful in designing future actions to create or optimise existing organisational models for the care of RDs in case of future emergencies or any other situation that might threaten the provision of routine care. These policies and plans should benefit from the multi-stakeholder RDs networks (such as the European Reference Networks), that should join forces at European, national, and local levels to minimise the economic, organisational, and health-related impact and the negative effects of potential emergencies on the RDs community. In order to design and develop these policies and plans, a decalogue of points to consider were developed to ensure appropriate care for people living with RDs in the case of eventual future health emergencies.

Identifiants

pubmed: 33238523
pii: ijerph17228694
doi: 10.3390/ijerph17228694
pmc: PMC7700629
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Ann Ist Super Sanita. 2017 Apr-Jun;53(2):170-175
pubmed: 28617266
Pulmonology. 2020 May - Jun;26(3):117-118
pubmed: 32291202
Am J Public Health. 2007 Apr;97 Suppl 1:S9-11
pubmed: 17413078
Eur J Med Genet. 2020 Sep 12;63(12):104062
pubmed: 32931946
Ann Ist Super Sanita. 2019 Jul-Sep;55(3):276-282
pubmed: 31553323

Auteurs

Rosaria Talarico (R)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana Rheumatology Unit, University of Pisa, 56126 Pisa, Italy.

Diana Marinello (D)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana Rheumatology Unit, University of Pisa, 56126 Pisa, Italy.

Sara Cannizzo (S)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana Rheumatology Unit, University of Pisa, 56126 Pisa, Italy.
Institute of Management, Scuola Superiore Sant'Anna, 56127 Pisa, Italy.

Andrea Gaglioti (A)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana Rheumatology Unit, University of Pisa, 56126 Pisa, Italy.

Simone Ticciati (S)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana Rheumatology Unit, University of Pisa, 56126 Pisa, Italy.

Claudio Carta (C)

National Centre for Rare Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Yllka Kodra (Y)

National Centre for Rare Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Mojgan Azadegan (M)

Tuscan Regional Center for Gender Specific Medicine, Azienda Ospedaliero Universitaria Pisana, 56126 Pisa, Italy.

Domenica Taruscio (D)

National Centre for Rare Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Marta Mosca (M)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana Rheumatology Unit, University of Pisa, 56126 Pisa, Italy.
Rheumatology Unit, University of Pisa, 56126 Pisa, Italy.

Giuseppe Turchetti (G)

Institute of Management, Scuola Superiore Sant'Anna, 56127 Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH